Effects of imatinib on normal hematopoiesis and immune activation.
about
Avian influenza viruses inhibit the major cellular signalling integrator c-Abl.The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaInterferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors.Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemiaImmunomodulatory effects of anti-angiogenic drugs.Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.CML as Part of Dual Malignancies-A Retrospective Analysis: Possible Mechanisms and Review of Literature.Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow.Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States.Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy.Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors.
P2860
Q30009343-29318FAC-0AC6-47AF-92F0-F11C2E15388BQ35628978-35391F24-690A-4231-9494-4E44E4BFFE22Q36597361-0A65FB20-72B0-4068-AAD6-06651B7839DCQ36974374-C5692B34-BF37-4C36-BB66-441C38352BE4Q37098840-799D50D9-2C48-4103-8CFD-1BAA8446A8BFQ37702242-46839511-C615-4FB3-BAE3-3B481A0B2378Q37847051-A647964C-B4C2-46EB-B23D-36FDE07031FBQ37853793-27BA8B2B-4028-4D59-A26B-8671321D28E8Q38095848-7D6BEDE6-CAA2-46CB-AE2F-27B3ECE082EFQ38221107-3DA3C395-83B3-4469-AD14-FBC9C299BDEEQ38998221-F92078C7-A034-488F-A56D-9832B949938BQ42372091-A73790D3-77CF-4B49-89E7-2922604D0FFFQ42839108-E7748F25-0ED9-46BD-AA3A-7A23A5DE30C0Q44679459-CFCEB967-ABA3-470A-B3E3-DEF725E21996Q46127678-9DA1F99C-57F6-4998-A302-D8994D4CB2E9Q47113340-EA709494-E2B5-44F9-8E75-2BFA3C82ACA7Q49873738-B9C512CB-1087-4AF0-BDDC-273211CD3706Q50457803-0103903B-6DB7-49D7-B07E-48304245F969Q50586934-220F4C0A-0770-471F-89F4-69C874CF7F7AQ54052684-FE13CBD0-F9A8-46C0-AC47-0183F3054265Q54281890-5CF835E6-0AAE-4DA7-8977-ED2008EE0E03
P2860
Effects of imatinib on normal hematopoiesis and immune activation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effects of imatinib on normal hematopoiesis and immune activation.
@ast
Effects of imatinib on normal hematopoiesis and immune activation.
@en
type
label
Effects of imatinib on normal hematopoiesis and immune activation.
@ast
Effects of imatinib on normal hematopoiesis and immune activation.
@en
prefLabel
Effects of imatinib on normal hematopoiesis and immune activation.
@ast
Effects of imatinib on normal hematopoiesis and immune activation.
@en
P2093
P1433
P1476
Effects of imatinib on normal hematopoiesis and immune activation
@en
P2093
Peter Brossart
Stefan Balabanov
Tim H Brümmendorf
P304
P356
10.1634/STEMCELLS.2005-0069
P50
P577
2005-09-01T00:00:00Z